首页> 外文期刊>Experimental and clinical transplantation >Prognostic Evaluation of Patients Undergoing Living-Donor Liver Transplant By APACHE II and MELD Scores
【24h】

Prognostic Evaluation of Patients Undergoing Living-Donor Liver Transplant By APACHE II and MELD Scores

机译:通过APACHE II和MELD评分评估接受活体供肝移植的患者的预后

获取原文
           

摘要

Objectives: We hypothesized that the combination of APACHE II and Model for End-Stage Liver Disease systems would work satisfactorily in patients admitted to intensive care unit after living-donor liver transplant. Materials and Methods: Data were retrospectively collected from the database of our surgical team. The study included 38 patients (hepatitis B virus cirrhosis, 47.4%; hepatocellular carcinoma, 28.9%; other diseases, 23.7%). Laboratory values were obtained. Vital signs, Glasgow Coma scale scores, and urine output were abstracted. Variables included age, sex, acute physiology score, APACHE II score, APACHE II-predicted intensive care unit and hospital mortality, predicted length of intensive care unit, and hospital stay. Patients' actual length of intensive care unit and hospital stays, intensive care unit and hospital discharge status, and discharge location were recorded. Standardized mortality ratios were calculated. Discrimination and calibration of APACHE II were assessed. All patients were divided into 3 groups: Model for End-Stage Liver Disease score: >25, 18 to 25, and <18. Predicted hospital mortality was calculated and compared. Results: Mean APACHE II scores of survivors and nonsurvivors were 13.03 and 23.67. Mean risk of death was 7.05% and 25.07%. APACHE II scores and risk of death between survivors and nonsurvivors was significantly different ( P < .001). The cutoff value of APACHE II score and Model for End-Stage Liver Disease score in the receiving operating characteristic curve was 20 and 25. Patients with APACHE II scores greater than 20 or Model for End-Stage Liver Disease scores greater than 25 had higher predicted hospital mortality after living-donor liver transplant. Conclusions: The modified APACHE II model provides an accurate prognosis of patients receiving a living-donor liver transplant. The combined application of Model for End-Stage Liver Disease score and APACHE II score can improve the predictive accuracy.
机译:目的:我们假设APACHE II和终末期肝病系统模型的组合在活体供肝肝移植后入住重症监护病房的患者中可以令人满意地工作。材料和方法:数据回顾性地从我们手术团队的数据库中收集。该研究包括38例患者(乙型肝炎病毒肝硬化,占47.4%;肝细胞癌,占28.9%;其他疾病,占23.7%)。获得实验室值。提取生命体征,格拉斯哥昏迷量表评分和尿量。变量包括年龄,性别,急性生理学评分,APACHE II评分,APACHE II预测的重症监护病房和医院死亡率,预测的重症监护病房长度和住院时间。记录患者的重症监护病房实际长度和住院时间,重症监护病房和医院出院状态以及出院位置。计算标准化死亡率。评估了APACHE II的鉴别和校准。所有患者分为3组:终末期肝病模型评分:> 25、18至25和<18。计算并比较了预测的医院死亡率。结果:幸存者和非幸存者的平均APACHE II评分分别为13.03和23.67。平均死亡风险为7.05%和25.07%。幸存者和非幸存者之间的APACHE II评分和死亡风险有显着差异(P <.001)。接受手术特征曲线中APACHE II评分和终末期肝病模型评分的临界值为20和25。APACHEII得分大于20或末期肝病模型评分大于25的患者具有更高的预测值活体供肝移植后的医院死亡率。结论:改良的APACHE II模型可为接受活体供肝移植的患者提供准确的预后。终末期肝病模型评分和APACHE II评分的组合应用可以提高预测准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号